Cheplapharm Arzneimittel, a German pharmaceutical company, agreed to acquire Astellas Pharma's Products Rights for five legacy products in Europe, Russia, CIS, and Asia for €95m. After closing of the investment, which is scheduled for September 2021, Cheplapharm will take over the marketing authorizations for the products in close collaboration with Astellas in order to ensure continuity of supply for these key medicines forpatients.